---
layout: default
title: Polatuzumab Vedotin
parent: 僅模型預測 (L5)
nav_order: 355
evidence_level: L5
indication_count: 10
---

# Polatuzumab Vedotin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the evidence pack as given — I'll flag upfront that this candidate is a low-confidence / likely-noise case, since the pack's own rationale text argues against the top prediction.

# Polatuzumab Vedotin: From CD79b-Positive B-Cell Malignancies to HER2-Positive Breast Carcinoma

## One-Sentence Summary

Polatuzumab vedotin is an anti-CD79b antibody-drug conjugate (ADC) carrying the microtubule inhibitor MMAE, developed for CD79b-positive B-cell malignancies such as DLBCL. The TxGNN model predicts it may be effective for **HER2-Positive Breast Carcinoma** with a very high similarity score (99.34%), but **0 clinical trials and 0 relevant publications** currently support this direction — the model's own repurposing rationale flags this as a likely target mismatch rather than a genuine biological signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not on file for Denmark; drug is developed for CD79b-positive B-cell malignancies (e.g., DLBCL), per mechanism-of-action context in the evidence pack |
| Predicted New Indication | HER2 Positive Breast Carcinoma |
| TxGNN Prediction Score | 99.34% |
| Evidence Level | L5 (model prediction only — no supporting clinical trials or valid literature) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Formal mechanism-of-action data for this candidate is marked as a data gap (DG002). However, the evidence pack's own repurposing rationale describes polatuzumab vedotin as an anti-CD79b antibody-drug conjugate: the antibody targets CD79b, a component of the B-cell receptor complex expressed on malignant B lymphocytes, and delivers the cytotoxic payload MMAE upon internalization. Its established target population is CD79b-positive B-cell malignancies (e.g., DLBCL).

HER2 is a receptor tyrosine kinase expressed on breast epithelial cells and is biologically unrelated to CD79b. Breast cancer cells do not express CD79b, so there is no known target-based pathway connecting this drug to HER2-positive breast carcinoma. The evidence pack explicitly characterizes the high TxGNN score (0.993) as likely reflecting knowledge-graph embedding similarity rather than an actual shared biological mechanism, and labels it as suspected **graph noise / target mismatch**. The same caveat applies to the other predicted indications in this pack (progesterone-receptor status, "normal breast-like" subtype, luminal A/B) — none have a plausible mechanistic link to CD79b/ADC biology.

Notably, one lower-ranked prediction ("breast tumor luminal A or B") did surface 19 PubMed hits, but on inspection these are all false-positive keyword matches — hepatitis B vaccine studies, B-cell developmental biology, HLA-B allele typing, and unrelated physics papers — triggered by the letter "B" in "luminal B" rather than any topical relevance. None of the 19 papers concern breast cancer or this drug. This is a useful caution: a nonzero literature count in this pack does not by itself indicate genuine evidentiary support.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

*Note: A related predicted indication ("breast tumor luminal A or B", same evidence tier) returned 19 PubMed hits, but all were confirmed to be keyword-mismatch noise (hepatitis B vaccines, B-cell biology, HLA-B typing, unrelated physics) with no relevance to breast cancer or this drug — none qualify as supporting evidence.*

## Denmark Market Information

No marketing authorisations are currently on file for this drug in Denmark (0 licenses recorded; market status: Not marketed).

## Cytotoxicity

Polatuzumab vedotin is an antibody-drug conjugate delivering a cytotoxic payload and targets a malignancy indication, so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy — antibody-drug conjugate (ADC) with cytotoxic payload (MMAE, a microtubule inhibitor) |
| Myelosuppression Risk | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Emetogenicity Classification | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Monitoring Items | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |
| Handling Protection | Please refer to the Summary of Product Characteristics (SmPC) warnings and precautions |

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

*Note: Retrieval of Danish SmPC warnings/contraindications is a blocking data gap (DG001) — this must be resolved before any safety-stage (S1) evaluation can proceed.*

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication (HER2-positive breast carcinoma) has no clinical trials, no valid literature support, and the evidence pack's own rationale identifies it as a likely target mismatch/graph-embedding artifact rather than a biologically plausible repurposing signal — CD79b and HER2 are unrelated targets with no known mechanistic overlap. All other predicted indications in this candidate set share the same weakness.

**To proceed, the following is needed:**
- Danish SmPC warnings, contraindications, and drug interaction data (blocking gap, DG001)
- Formal, sourced mechanism-of-action documentation (DG002)
- Independent biological/target-expression validation before treating this TxGNN score as a genuine repurposing signal (e.g., confirm whether HER2-positive breast tumors express any CD79b-related target)
- If pursued further, re-run literature/trial searches with disambiguated disease terms to avoid keyword-collision noise (as seen with the "luminal B" false positives)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

